LONDON, Jan 29 (Reuters) – Tom Stoppard, the grand old man
of British theatre, is back with his first new stage play in
nine years, tackling typically big ideas: consciousness, science
“The Hard Problem” is a 100-minute gallop, with no interval,
through neurobiology, religion and improbable “black swan”
events in financial markets that is both contemporary and
timeless. Along the way there are tales of altruistic vampire
bats and some good jokes.
LONDON (Reuters) – AstraZeneca said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases.
The academic and commercial tie-ups will allow British-based AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine.
DAVOS, Switzerland (Reuters) – A steep fall in Ebola cases in Liberia will make it hard to prove whether experimental vaccines work in a major clinical trial about to start in the country, the head of the U.S. National Institutes of Health (NIH) said on Saturday.
The NIH might have to move some testing to neighboring Sierra Leone, while regulators could end up approving Ebola shots based on efficacy data from animal tests backed by only limited human evidence, Francis Collins told Reuters.